SCOTT MEDICAL'S ISPAN OPHTHALMIC GASES WILL BE MARKETED BY ALCON SURGICAL
This article was originally published in The Gray Sheet
Executive Summary
Alcon Surgical will market Scott Medical's Ispan Ophthalmic gases under an exclusive worldwide agreement between the two firms. Scott Medical's Ispan C3F8 perfluoropropane gas and Ispan SF6 sulfur hexafluoride gas were both approved by FDA Feb. 25 for use as an aid in the treatment of uncomplicated retinal detachment via pneumatic retinopexy. C3F8 is absorbed by the eye six weeks after injection and SF6 in 10 days. The gases were recommended for approval by FDA's ophthalmic devices panel in April 1991 ("The Gray Sheet" April 22, 1991, I&W-3).
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.